Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated June 15, 2022, reports the execution of an Executive Employment Agreement with Ms. Melissa Bradford-Klug. The agreement appoints her as Chief Operating Officer, effective July 1, 2022, reporting to President and CEO Rachelle Jacques.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
- Base Salary: $440,000 annually.
- Annual Cash Bonus: Target of 45% of base salary (pro-rated for 2022).
- Performance Bonus: $200,000 total, payable in two installments upon milestone achievement.
- Stock Option Grant: 40,000,000 ordinary shares, granted in two increments (50% within 30 days of start date, 50% six months later).
- Vesting Schedule: Ratably on a semiannual basis over four years.
Material Changes
The primary material change is the addition of a senior executive to the leadership team. Ms. Bradford-Klug brings experience from RareStone Group, Mayfield Pharmaceuticals (now Harrow Health), Keryx Biopharmaceuticals, AMAG Pharmaceuticals, Mallinckrodt, Baxter International, Eli Lilly, and Monsanto.
Guidance, Outlook, and Risks
The filing contains no financial guidance or market outlook. Key contingencies and risks relate to the employment agreement terms:
- Termination Provisions: The agreement outlines specific severance packages for termination without cause (12 months of base salary and target bonus) and acceleration of stock options in the event of a change in control followed by termination without cause or for good reason.
- Confidentiality: The agreement includes restrictive covenants and confidentiality requirements.
Investor Verification Checklist
- Verify the dilution impact of the 40,000,000 share option grant on existing shareholders.
- Confirm the specific performance milestones required to trigger the $200,000 performance bonus.
- Review the full Employment Agreement filed as an exhibit to the 2022 Form 20-F for detailed legal terms.
- Assess the company's cash burn rate relative to the new executive compensation obligations.